Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | CELG | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.03% | 110.05 | 110.26 | 109.71 | 110.23 | 110.02 | 15:27:39 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 110.05 | 110.06 | 0.01 | 0.01% | - | 2 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 25,633 | 2,700,034 | $ 110.11 | $ 297,293,859 | 4,086,851 | 58.59 - 110.70 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:27:39 | 69 | $ 110.05 | USD |
Celgene Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 78.32B | 711.71M | $ 4.05B | 5.52 | 13.40 | 707.88M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Celgene News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CELG Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 108.95 | 110.70 | 108.69 | 109.87 | 3,964,054 | 1.10 | 1.01% |
| 1 Month | 102.20 | 110.70 | 101.69 | 107.38 | 3,945,012 | 7.85 | 7.68% |
| 3 Months | 95.65 | 110.70 | 93.41 | 101.87 | 3,525,905 | 14.40 | 15.05% |
| 6 Months | 93.74 | 110.70 | 89.03 | 97.46 | 3,681,568 | 16.31 | 17.4% |
| 1 Year | 69.28 | 110.70 | 58.59 | 88.39 | 6,511,442 | 40.77 | 58.85% |
| 3 Years | 120.08 | 147.17 | 58.59 | 97.37 | 5,713,318 | -10.03 | -8.35% |
| 5 Years | 103.27 | 147.17 | 58.59 | 102.56 | 5,287,547 | 6.78 | 6.57% |
Celgene Description
| Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline. |
